Since there is an urgent need for the development of novel therapeutics that target Cancer Stem Cells (CSC), we have developed/identified novel pathways and agents that affect their self-renewal, regeneration or differentiation processes
Transgenex has identified a set of inhibitors of a signaling pathway which regulates tumor and stromal cell interactions and expansion of CSC during caricnogenesis
Using in-house developed FiSS platform technology and high throughput screening methods, TGN's drug development pipeline currently comprises of following four candidate molecules
